Unravelling the druggability and immunological roles of the SOCS-family proteins

Front Immunol. 2024 Nov 29:15:1449397. doi: 10.3389/fimmu.2024.1449397. eCollection 2024.

Abstract

The Suppressor of Cytokine Signalling (SOCS) protein family play a critical role in cytokine signalling and regulation of the JAK/STAT pathway with functional consequences to the immune response. Members of this family are implicated in multiple different signalling cascades that drive autoimmune diseases and cancer, through their binding to phosphotyrosine modified proteins as well as ubiquitination activity as part of Cullin5 RING E3 ligases. Here we review the SOCS family members CISH and SOCS1-SOCS7, with a focus on their complex role in immunity. The interactome and signalling network of this protein family is discussed, and the intricate mechanisms through which SOCS proteins alter and manage the immune system are assessed. We offer structural insights into how SOCS proteins engage their interacting partners and native substrates at the protein-protein interaction level. We describe how this knowledge has enabled drug discovery efforts on SOCS proteins to date and propose strategies for therapeutic intervention using small molecules, either via direct inhibition or leveraging their E3 ligase activity for targeted protein degradation.

Keywords: Cullin RING E3 ligases; E3 ligases; SH2 domains; SOCS proteins; cell signalling; phosphotyrosine (pTyr); small molecule inhibitors; targeted protein degradation.

Publication types

  • Review

MeSH terms

  • Animals
  • Drug Discovery
  • Humans
  • Protein Binding
  • Signal Transduction*
  • Suppressor of Cytokine Signaling Proteins* / chemistry
  • Suppressor of Cytokine Signaling Proteins* / metabolism
  • Ubiquitination

Substances

  • Suppressor of Cytokine Signaling Proteins

Grants and funding

The author(s) declare that financial support was received for the research, authorship, and/or publication of this article. Research in the Ciulli laboratory on targeting SOCS proteins has received funding from the European Research Council (ERC) under the European Union’s Seventh Framework Programme (FP7/2007-2013) as a Starting Grant to AC (grant agreement ERC-2012-StG-311460 DrugE3CRLs), Nurix Therapeutics, and the Innovative Medicines Initiative 2 (IMI2) Joint Undertaking under grant agreement No 875510 (EUbOPEN project to AC) from the European Union’s Horizon 2020 research and innovation programme. The IMI2 Joint Undertaking receives support from the European Union’s Horizon 2020 research and innovation program, European Federation of Pharmaceutical Industries and Associations (EFPIA) companies, and associated partners KTH, OICR, Diamond, and McGill. TW is funded by a PhD studentship from the UK Medical Research Council (MRC) under the Industrial Cooperative Awards in Science & Technology (iCASE award with AstraZeneca) doctoral training programme MR/R015791/1.